small nucleolar RNA, H/ACA box 5AGenealiases: ACA5 · ACA5A/B/C
Q-omics provides the consensus-scored SNORA5A profile across patient tissues and cancer cell-line models. SNORA5A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SNORA5A is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SNORA5A RNA expression shows 16,759 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, COAD, and UVM as cancer lineages where SNORA5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA5A survival associations across molecular data types. SNORA5A RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA5A RNA expression–survival associations across cancer types. High SNORA5A expression shows unfavorable associations in THCA, UVM, LGG, ACC and KIRC, but favorable associations in READ. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify THCA as the clearest survival context for SNORA5A RNA expression.
This table summarizes SNORA5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA5A shows lower tumor expression in THCA and higher tumor expression in COAD, KIRC, HNSC, READ and LUAD. The COAD box plot shows higher SNORA5A RNA expression in tumor versus normal tissue (log2 FC = +1.267, t-test p < 0.001).
This table shows molecular features associated with SNORA5A in patient tissues and cancer cell lines. In patient samples, SNORA5A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
